Core Viewpoint - The national drug supervision work conference emphasized key tasks for 2026 to ensure a good start for the "14th Five-Year Plan," focusing on drug safety, industry development, legal standards, and modernization of drug regulation [1] Group 1: Drug Safety - The conference highlighted the need to ensure high-level drug safety by improving the drug safety responsibility system and enhancing clinical trial supervision [1] - There will be increased inspection and sampling efforts on key varieties, especially those selected in centralized procurement [1] - The initiative includes a "clean source" action in drug distribution and strengthened regulation of online sales to maintain drug safety standards [1] Group 2: Industry Development - The conference aims to support the pharmaceutical industry in improving quality and efficiency through comprehensive reform of drug regulation [1] - It emphasizes early intervention and tailored strategies for key products, promoting innovation in drug research and development [1] - The focus also includes supporting the self-reliance of high-level medical devices and fostering the growth of the beautiful economy [1] Group 3: Legal Framework - Continuous improvement of the drug regulation legal framework is a priority, including enhancing the authority and credibility of administrative law enforcement [1] - There will be increased legal education efforts directed at enterprises and grassroots levels to solidify the legal foundation of drug regulation [1] Group 4: Modernization of Drug Regulation - The conference calls for high-quality development of the "14th Five-Year" drug planning and the promotion of integrated national drug regulation [1] - Strengthening the regulatory talent pool and technical support capabilities is essential, along with advancing regulatory information technology and scientific research applications [1] - The initiative aims to enhance China's international influence in drug regulation and participate actively in global drug safety governance [1]

（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：请问公司在脑机接口领域进展如何？ 赛诺医疗（688108.SH）1月7日在投资者互动平台表示，脑机接口作为当前最具颠覆性的前沿技术之 一，近年来受到大家的广泛关注。赛诺医疗是一家专注于高端介入医疗器械研发、生产、销售的国际化 公司，一直密切关注包括脑机接口在内的行业新技术及其应用的发展，并将其作为公司重点探讨的战略 方向之一。但截至目前，我公司在售产品中，尚无可以直接应用于脑机接口的相关产品。请您注意投资 风险，谨慎投资。 ...

然而，这一"金标准"长期以来却面临着巨大的临床困境。传统的核型分析完全依赖人工操作，耗时很 长，对操作者的经验要求也极高，行业平均准确率仅约50%左右，报告周期长达30天左右。 重塑传统工作流程：全自动细胞实验流水线 由于对设备和技术的要求极高，卡尔蔡司、徕卡等国际巨头长期占据染色体核型分析95%以上的市场份 额。面对强大的市场需求和国产设备的空白，德适生物选择了一条创新道路，基于iMedImage™基座模 型研发的智能设备与系统，包括AI AutoVision®染色体核型辅助诊断软件、AutoVision®染色体分析软 件、KayoFlow®自动细胞收获仪、KayoFlow®制片染色一体机、MetaSight®自动细胞显微图像扫描系统 等，既可独立使用，也可组合使用，形成一套高度集成的自动化细胞实验流水线，成为其打破行业困局 的"核心武器"。它覆盖染色体核型分析的四大关键环节：细胞收获、制片染色、图像采集与智能分析， 实现"从样本进到结果出"的全流程自动化和标准化。 (图为2025年广交会现场客商聚集在德适生物展品前) 1月6日，杭州德适生物科技股份有限公司向香港联交所主板递交上市申请。这是德适生物继202 ...

Group 1 - The company has significantly increased its R&D investment in recent years, focusing on fields such as radiotherapy, minimally invasive endoscopy, and rehabilitation intelligent devices [1] - The company has achieved phased breakthroughs, resulting in the registration of multiple new products and international certifications [1] - The core competitiveness of the company is steadily improving as a result of these efforts [1]

最新公告列表 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 《第三届董事会第十九次会议决议公告》 《2025年限制性股票激励计划预留权益授予的激励对象名单》 《广东东方昆仑(东莞)律师事务所关于惠州市锦好医疗科技股份有限公司2025年第四次临时股东 会法律意见书》 《2025年第四次临时股东会决议公告》 截至2026年1月7日收盘，锦好医疗（920925）报收于27.84元，较前一交易日下跌14.76%，最新总市值 为27.41亿元。该股当日开盘31.44元，最高31.44元，最低27.38元，成交额达5.17亿元，换手率为 32.59%。 近日，惠州市锦好医疗科技股份有限公司公布2025年限制性股票激励计划预留权益授予名单，共授予3 名激励对象200,000股限制性股票。其中，高级管理人员张亮获授100,000股，占比50.00%；袁金鹏获授 50,000股，占比25.00%；核心员工钟梅获授50,000股，占比25.00%。上述股份合计占公司总股本的 0.20%。 ...

| | | | | | 交易日期 2026-01-07 | | | --- | --- | --- | --- | --- | --- | --- | | | | | | | 证券简称 澳华内樓 | | | 证券代码 688212 42.76 | 2679.77 | 成交价(元) 成交金额(万元) 成交量( *) 买入营业部 62.67 | 机构专用 | 卖出营业部 茶里里多里多里 | | 是否为专场 KO | 1月7日，澳华内镜大宗交易成交62.67万股，成交额2679.77万元，占当日总成交额的17.95%，成交价 42.76元，较市场收盘价46.48元折价8%。 ...

Group 1 - The core point of the article is that Opcon Vision has reported an expected total number of shareholders to reach 61,940 by December 31, 2025 [2]

Core Viewpoint - The leading domestic surgical robot company, Precision Medical (2675.HK), is set to be listed in Hong Kong, with a significant increase in its dark pool trading price, reflecting strong market interest and investor confidence [1] Group 1: Company Overview - Precision Medical is an advanced surgical robot company in the medical device industry, focusing on the design, development, and manufacturing of surgical robots [1] - The company has three models of products at different stages of research and development, targeting the market potential of surgical robots, including multi-port laparoscopic surgical robots, single-port laparoscopic surgical robots, and natural orifice surgical robots for non-invasive procedures [1] Group 2: IPO Details - The IPO involves a global offering of 27.72 million shares, priced at HKD 43.24 per share [1] - As the third surgical robot enterprise listed domestically, Precision Medical has attracted a prestigious lineup of cornerstone investors, including the Abu Dhabi Investment Authority, UBS Asset Management, Obor Capital, and Tencent, with a total subscription amount of USD 75 million [1]

中国质量新闻网讯 2025年以来，天津市市场监管委紧扣高质量发展"十项行动"与市场监管"五大工 程"，组织指导全市市场监管部门以"广告+N"专题计划为蓝图，积极推进广告助企惠农、产学研融合发 展，取得积极成效。 聚焦产业赋能，打造广告助企惠农新范式。以"文化为魂，创新为翼"为核心理念，促成10家龙头传媒与 36家老字号企业开展交流合作，为老字号品牌焕新、精准传播和数字化转型提供一站式服务。组织传媒 企业深入对接8个涉农经营主体与相关乡镇政府，提供品牌体系构建、商标创意设计和多元渠道拓展等 综合支持方案，搭建线上公益性宣传推广平台。 北辰区市场监管局启动重点企业风险会商机制，组建由执法业务骨干、行业专家组成的研判团队，与企 业代表共同梳理行业痛点，建立动态更新的行业风险数据库，对重点企业、高风险产品及关键营销时段 实施24小时动态监测，形成"风险识别—分析研判—预警处置"闭环管理，实现风险早识别、早处置。深 化"一企一策"服务机制，联合多部门提供一站式合规服务，为13家企业量身定制方案，指导21家建立审 核机制。建立分行业精准指导机制，针对食品、药品、医疗器械等领域组织4场合规座谈会，覆盖辖区 135家经营主体 ...

| 洗及出区和国家 | 中国 | | --- | --- | | 涉及产品生产(或进口 | 1500 支 | | 中国)批次、数量 | 7 | | 识别信息 | H 20250402 | | (如批号) | ਦਿ | | 召回原因简述 | 一次性使用吸痰管在陕I | | 纠正行动简述(包括召回 | 1、产品均已销售完毕,故无 2、已销售的产品发出台回遇 | | 要求和处理方式等) | 3、对召回的产品做技发处理 | | (盖章 报告单位: | 扬州伊贝康医疗科技有 | | (答 报 告 人: | | | 产品名称 | 一次性使用吸痰管 | 注 | | --- | --- | --- | | 生产企业名称 | | 扬州伊 | | 代理人名称 | | | | 召回单位负责人和联系 方式,经办人和联系方式 | | 場 | | 产品的适用范围 | | | 扬州伊贝康医疗科技有限公司报告，由于在陕西省局监督抽检中出现接头内径项目不符合要求的问题，扬州伊贝康医疗科技有限公司对其生产的一次性使用 吸痰管主动召回。召回级别为三级。涉及产品的型号、规格及批次等详细信息见《医疗器械召回事件报告表》。 ...